Scholar Rock Holding Corp
SRRKNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | — | — | $33.2M | $18.8M | $15.4M |
| Operating income | −$384.6M | −$252.1M | −$171.3M | −$134.4M | −$129.9M | −$86.9M |
| Net income | −$377.9M | −$246.3M | −$165.8M | −$134.5M | −$131.8M | −$86.5M |
| Total assets | $404.3M | $474.9M | $311.0M | $358.2M | $304.4M | $388.3M |
| Total liabilities | $158.8M | $106.3M | $85.8M | $97.9M | $132.4M | $127.5M |
| Equity | $245.5M | $368.6M | $225.2M | $260.2M | $172.1M | $260.8M |
| EPS (diluted) | $-3.29 | $-2.47 | $-1.99 | $-2.26 | $-3.59 | $-2.81 |
| Shares out. | 94.7M | 77.9M | 52.0M | 35.3M | 34.3M | 29.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −154.0%
- Return on assets
- −93.5%
- Return on capital (ROCE)
- −110.3%
- Liabilities / assets
- 39.3%
- Debt / equity
- 0.65×
- Book value / share
- $2.59
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -9.91distress
- Accruals / assets
- −19.3%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Redmile Group, LlcPassive (13G)May 15, 2026
- Price T Rowe Associates Inc /Md/Passive (13G)May 15, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Wellington Management Group LlpPassive (13G)Feb 10, 2026
- Samsara Biocapital, L.P.Activist (13D)Oct 7, 2025
- Invus Global Management, LlcPassive (13G)Feb 12, 2025
- Fmr LlcPassive (13G)Feb 12, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Burow KristinaDirector | Apr 23, 2026 | Option exercise | 7,800 | $26.78 |
| Woods KeithOfficer — Chief Operating Officer | Apr 16, 2026 | Sell | 10,220 | $49.57 |
| Vaishnaw AkshayOfficer — President of R&D | Apr 16, 2026 | Sell | 12,246 | $49.57 |
| Sinha VikasOfficer — Chief Financial Officer | Apr 16, 2026 | Sell | 10,410 | $49.57 |
| Hallal DavidOfficer — Chief Executive Officer | Apr 16, 2026 | Sell | 30,615 | $49.57 |
| Qatanani MoOfficer — CHIEF SCIENTIFIC OFFICER | Feb 23, 2026 | Sell | 7,427 | $46.94 |
| Marantz Jing L.Officer — CHIEF MEDICAL OFFICER | Feb 17, 2026 | Sell | 4,157 | $46.53 |
| Ho JunlinOfficer — GENERAL COUNSEL | Feb 17, 2026 | Sell | 9,580 | $46.53 |
| Parlavecchio CarynOfficer — CHRO | Feb 17, 2026 | Sell | 9,035 | $46.53 |
| Qatanani MoOfficer — CHIEF SCIENTIFIC OFFICER | Feb 17, 2026 | Sell | 7,989 | $46.53 |
| Vaishnaw AkshayOfficer — President of R&D | Feb 9, 2026 | Grant | 47,021 | $0.00 |
| Sinha VikasOfficer — Chief Financial Officer | Feb 9, 2026 | Grant | 47,021 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 15.7M | 11.9 | +5.1% |
| Apr 30, 2026 | 14.9M | 10.8 | +0.6% |
| Apr 15, 2026 | 14.8M | 9.6 | -5.9% |
| Mar 31, 2026 | 15.7M | 7.9 | +10.1% |
| Mar 13, 2026 | 14.3M | 8.8 | -1.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Regulation FD disclosureMay 7, 2026
- Regulation FD disclosure · Other material eventMar 31, 2026
- Results of operations · Regulation FD disclosureMar 3, 2026
- Results of operations · Regulation FD disclosure · Other material eventJan 12, 2026
- Other material eventDec 2, 2025
- Other material eventNov 14, 2025
- Results of operations · Regulation FD disclosureNov 14, 2025
- Other material eventOct 14, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- 10-QMay 7, 2026
- 8-KMay 7, 2026
- 4OWNERSHIP DOCUMENTApr 24, 2026
- ARSApr 22, 2026
- DEFA14AApr 22, 2026
- DEF 14AApr 22, 2026
- 4OWNERSHIP DOCUMENTApr 20, 2026
- 4OWNERSHIP DOCUMENTApr 20, 2026
- 4OWNERSHIP DOCUMENTApr 20, 2026
- 4OWNERSHIP DOCUMENTApr 20, 2026
- 144Apr 6, 2026
- 8-KFORM 8-KMar 31, 2026
- SCHEDULE 13G/AMar 27, 2026